The efficacy outcomes were the ratio of urine albumin creatine ratio at posttreatment versus at baseline (mean difference: -0.30; 95% confidence interval [CI; -0.32, -0.27]; P < .00001; I2 = 0%), the primary composite outcome (hazard ratio [HR]: 0.81; 95% CI [0.76, 0.87]; P < .00001; I2 = 13%), the secondary composite outcome (HR: 0.82; 95% CI [0.74, 0.91]; P = .0001; I2 = 0%), kidney failure (HR: 0.76; 95% CI [0.70, 0.83]; P < .00001; I2 = 0%), and the risk of end stage kidney disease (HR: 0.87; 95% CI [0.77, 0.99]; P = .03; I2 = 46%). This evidence concerns the gene ALB and kidney failure.